The Bio Report

Artificial intelligence is all the rage in drug discovery today, but there are efforts to apply to technology to other aspects of the drug development continuum to improve decision making and increase efficiency. One such example is Phesi, which has developed an artificial intelligence platform to improve clinical site selection, evaluate protocol designs and patient inclusion criteria, and manage the implementation of trials. We spoke to Gen Li, founder and president of Phesi, about his company’s AI platform, how it works, and the case for the use of artificial intelligence as a tool to improve drug development.